ABRAXANE® for advanced non-small cell lung cancer (NSCLC)

CHOOSE FIRST-LINE
ABRAXANE + CARBOPLATIN

FOR ADVANCED NSCLC,
INCLUDING SQUAMOUS

CHOOSE FIRST-LINE
ABRAXANE + CARBOPLATIN

FOR ADVANCED NSCLC, INCLUDING SQUAMOUS

National Comprehensive Cancer Network® recommendation - image

ALBUMIN-BOUND PACLITAXEL (ABRAXANE) + CARBOPLATIN: NCCN CATEGORY 1a RECOMMENDED FIRST-LINE OPTION FOR METASTATIC NSCLCb
  • aCategory 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
  • bPerformance status 0-1; EGFR, ALK, ROS-1, BRAF, and PD-L1 negative or unknown.
SIGNIFICANTLY SUPERIOR ORR
IN THE ITT POPULATION

33% ABRAXANE® + carboplatin (95% CI: 28.6%-36.7%) vs 25% paclitaxel + carboplatin (95% CI: 21.2%-28.5%) overall response rate for ITT population in advanced non-small cell lung cancer (aNSCLC) from phase III trial - chart

  • Median duration of response was 6.9 months vs 6.0 months (95% CI: 5.6-8.0 months vs 5.6-7.1 months, respectively)
  • No statistically significant difference in overall survival between the 2 study arms (median OS 12.1 months vs 11.2 months, P=NS11)
ESTABLISHED SAFETY PROFILE
Common ARs (≥10%) for ABRAXANE + carboplatin:

Anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea, and fatigue

41% ORR IN SQUAMOUS PATIENTS

ABRAXANE® + carboplatin (41%) vs paclitaxel + carboplatin (24%) overall response rate in advanced non-small cell lung cancer (aNSCLC) squamous subpopulation from phase III trial - chart

ORR IN PATIENTS WITH
NONSQUAMOUS ADVANCED NSCLC
ORR IN PATIENTS WITH
NONSQUAMOUS ADVANCED NSCLC

Clinical trial; ABRAXANE® + carboplatin vs paclitaxel + carboplatin ORR in advanced NSCLC by histology - chart

ESTABLISHED SAFETY PROFILE
Common ARs (≥10%) for ABRAXANE + carboplatin:

Anemia, neutropenia, thrombocytopenia, alopecia, peripheral neuropathy, nausea, and fatigue

STUDY DESIGN

Multicenter, 1:1 randomized, phase III study comparing ABRAXANE (100 mg/m2 IV; Days 1, 8, and 15 of each 21-day cycle) + carboplatin (AUC=6 mg•min/mL IV, Day 1 of each 21-day cycle) with paclitaxel injection (200 mg/m2 IV, Day 1 of each 21-day cycle) + carboplatin (AUC=6 mg•min/mL IV, Day 1 of each 21-day cycle) in 1052 chemonaïve patients with NSCLC.

  • ITT=intent-to-treat; ORR=overall response rate.
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation

The clinical trial described in this article served as the
basis for the approval for ABRXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.

Please see Important Safety Information and Prescribing Information, including Boxed WARNING.

Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com

OK
CANCEL